Solid state forms of tapentadol salts
View Patent ↗Provided herein are novel solid state forms of tapentadol salts, process for their preparation, pharmaceutical compositions, and method of treating thereof. The tapentadol salts include an L-(−)-camphorsulfonate salt, a dibenzoyl-(L)-tartrate salt, a dibenzoyl-(D)-tartrate salt, a malate salt, a maleate salt, or a salicylate salt.
1. Solid state form of a salt of 3-[(1R,2R)-3-(dimethylamino)-1-ethyl-2-methylpropyl] phenol (tapentadol salt), wherein the salt of tapentadol is a dibenzoyl-(L)-tartrate salt, characterized by one or more of the following properties:
i) a powder X-ray diffraction pattern in accordance with FIG. 3 ;
ii) a powder X-ray diffraction pattern having peaks at 4.83, 5.76, 9.61, 16.08, 17.40 and 17.82±0.2 degrees 2-theta;
iii) a powder X-ray diffraction pattern having peaks at 4.83, 5.76, 9.61, 11.72, 13.26, 14.39, 16.08, 17.19, 17.40, 17.82, 18.14, 18.90, 19.19, 20.88, 21.53, 21.88, 22.43, 22.78, 23.31, 23.53, 24.06, 26.58, 27.26, 27.98, 31.22, 34.75 and 34.96±0.2 degrees 2-theta; and
iv) a differential scanning calorimetric (DSC) thermogram in accordance with FIG. 4 , wherein the dibenzoyl-(L)-tartrate salt of tapentadol is greater than 98% pure.
2. A pharmaceutical composition comprising solid state form of a tapentadol salt and one or more pharmaceutically acceptable excipients, wherein the salt of tapentadol is a dibenzoyl-(L)-tartrate salt according to claim 1 .
3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition is a solid dosage form, an oral suspension, a liquid, a powder, an elixir, an aerosol, a syrup, or an injectable solution.
4. The pharmaceutical composition of claim 2 , wherein the solid state form of tapentadol salt has a D 90 particle size of less than or equal to about 500 microns.
5. The pharmaceutical composition of claim 4 , wherein the D 90 particle size is about 1 micron to about 300 microns, or about 10 microns to about 150 microns.